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Abstract
Background: Denervation triggers numerous molecular responses in skeletal muscle, including the activation of catabolic
pathways and oxidative stress, leading to progressive muscle atrophy. Histone deacetylase 4 (HDAC4) mediates skeletal
muscle response to denervation, suggesting the use of HDAC inhibitors as a therapeutic approach to neurogenic muscle
atrophy. However, the effects of HDAC4 inhibition in skeletal muscle in response to long-term denervation have not been
described yet.
Methods: To further study HDAC4 functions in response to denervation, we analyzed mutant mice in which HDAC4 is
specifically deleted in skeletal muscle.
Results: After an initial phase of resistance to neurogenic muscle atrophy, skeletal muscle with a deletion of HDAC4 lost
structural integrity after 4 weeks of denervation. Deletion of HDAC4 impaired the activation of the ubiquitin-proteasome
system, delayed the autophagic response, and dampened the OS response in skeletal muscle. Inhibition of the ubiquitin-
proteasome system or the autophagic response, if on the one hand, conferred resistance to neurogenic muscle atrophy;
on the other hand, induced loss of muscle integrity and inflammation in mice lacking HDAC4 in skeletal muscle. Moreover,
treatment with the antioxidant drug Trolox prevented loss of muscle integrity and inflammation in in mice lacking HDAC4
in skeletal muscle, despite the resistance to neurogenic muscle atrophy.
Conclusions: These results reveal new functions of HDAC4 in mediating skeletal muscle response to denervation and lead
us to propose the combined use of HDAC inhibitors and antioxidant drugs to treat neurogenic muscle atrophy.
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Background
Loss of muscle innervation occurs in numerous disorders,
such as in amyotrophic lateral sclerosis (ALS) or in spinal
muscular atrophy (SMA), but also following viral infections
or during aging, accounting for a drastic loss of muscle
mass. Different molecular mechanisms, including the cata-
bolic pathways—e.g., the ubiquitin-proteasome system and
autophagy—and oxidative stress (OS), which are normally
involved in the maintenance of muscle homeostasis, are
activated following muscle denervation, thus contributing to
muscle atrophy [1–3]. Degradation through the ubiquitin-
proteasome system (UPS) is initiated by the sequential
addition of ubiquitin molecules to target proteins, catalyzed
by E1-, E2-, and E3-ubiquitinating enzymes. The polyubi-
quitinated proteins are then recognized and processed by
the proteasome, a multi-catalytic proteolytic complex.
Two key factors for inducing skeletal muscle atrophy
are the E3-ubiquitin ligases atrogin1 and MuRF1. Con-
sistently, mice lacking either factor are resistant to
neurogenic muscle atrophy [4]. Another catabolic pathway
activated in skeletal muscle following denervation is
autophagy [5, 6]. Damaged or dysfunctional intracellular
components are polyubiquitinated and included into
double-membrane structures, the autophagosomes, to
be degraded by autophagy. Several autophagy-related (Atg)
genes are induced and participate in the formation of the
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autophagosomes, while the cytosolic LC3bI is converted to
LC3bII, allowing its association with the developing autop-
hagosome membrane. The chaperone protein p62 binds to
polyubiquitinated proteins and to LC3b or Gabarapl1,
thus guiding the cargo into autophagosomes to be
digested [7–9]. Since p62 itself is degraded after the
fusion of autophagosomes with lysosomes, it is commonly
used as a marker for the evaluation of the autophagic flux
[10]. Although initially considered as a non-selective
degradation pathway, autophagy plays a role in the selective
removal of specific organelles, such as mitochondria (via
mitophagy) or protein aggregates. After depolarization
of the mitochondrial membrane or accumulation of
mitochondrial misfolded proteins, PINK1 is stabilized at
the outer mitochondrial membrane, where it phosphory-
lates and activates Park2 [11, 12], targeting mitochondria
for removal by autophagy [13, 14]. For a long time, UPS
and autophagy were considered independent pathways.
However, several proteins, e.g., α-synuclein or aggregate-
prone proteins, are known to share these two degradative
pathways [15–18], indicating that UPS and autophagy may
be interchangeable, depending on cellular necessity. Indeed,
the inhibition of either process has been shown to drive the
activation of the other in physiological contexts [19–23].
Besides activating the catabolic pathways, denervation
induces increasing levels of OS in skeletal muscle [24].
Oxidants damage cellular components and cause cellular
dysfunctions. To cope with OS, organisms have developed
multiple defense mechanisms to alleviate oxidative dam-
age, including antioxidants enzymes, molecular chaper-
ones, and proteolytic systems. Indeed, both autophagy and
UPS are activated in response to OS to remove damaged
proteins [25, 26].
Epigenetic processes fine-tune cellular responses to
different stresses, including denervation [26–29]. Class
II histone deacetylases (HDACs) are involved in the
transcriptional activation of the E3-ubiquitin ligases
atrogin1 and MuRF1 and the activation of the MAPK-AP1
axis following denervation [30, 31]; while Sirt1, HDAC6,
HDAC1, and HDAC2 have been shown to regulate
autophagy and therefore the maintenance of muscle
homeostasis [32–34].
HDAC4 is a member of class IIa HDACs, rapidly
induced in skeletal muscle upon denervation and able to
mediate skeletal muscle response. Following denervation,
HDAC4 indirectly regulates myogenin expression, thereby
connecting neuronal activity to skeletal muscle transcrip-
tional reprogramming of the neuromuscular junctions
and compensatory reinnervation [35]. Considering its
crucial role, HDAC4 has been proposed as a potential
therapeutic target for diseases characterized by neurogenic
muscle atrophy, such as ALS or SMA, or for sarcopenia
[36–39]. Any pharmacological treatment with HDAC4
inhibitors for these conditions should be continued for
months or years. However, the effects of HDAC4 inhib-
ition in skeletal muscle following long-term denervation
have not been investigated yet.
To delineate the role of HDAC4 in skeletal muscle in
a condition of long-term denervation, we cut the sciatic
nerve and analyzed skeletal muscle-specific HDAC4
mutant mice (hereafter referred to as HDAC4mKO mice)
over time. We demonstrate that inhibition of HDAC4 leads
to loss of muscle integrity and inflammation upon long-
term denervation, because of the impairment in the activa-
tion of the UPS and a delay in triggering the autophagic
pathway. Moreover, HDAC4mKO mice showed altered
OS response, and an antioxidant treatment reduced loss
of muscle integrity and inflammation in HDAC4mKO,
preserving resistance to neurogenic muscle atrophy.
These findings reveal that inhibition of HDAC4 could
be detrimental for skeletal muscle in a condition of
long-term denervation. However, the combined use of
antioxidant drugs and HDAC inhibitors may prove useful
in the treatment of ALS, SMA, and sarcopenia.
Methods
Mice
HDAC4 conditional mutant mice were previously gener-
ated and described [40]. Adult (10 weeks old) HDAC4fl/fl
myogenin;Cre (HDAC4mKO) and HDAC4fl/fl (control
mice) female mice were used throughout the experiments.
Mice were treated in strict accordance with the guidelines
of the Institutional Animal Care and Use Committee
and to national and European legislation, throughout
the experiments. Animal protocols were approved by
the Italian Ministry of Health (authorizations # 244/2013;
# 80/2014-B; # 138/2016-PR).
Denervation
In anesthetized adult mice, the sciatic nerve of the left
limb was cut, and a 3 mm piece was excised. The right
leg remained innervated and was used as control. Mice
were sacrificed at indicated time points for histological
and molecular analyses.
Colchicine administration
To assess autophagic flux, mice were treated with either
0.4 mg/kg/day colchicine (Sigma-Aldrich) or an equal
volume of vehicle (water), by daily intraperitoneal (i.p.)
injections, for 4 days prior to sacrifice, as previously
described [41].
Methylene blue administration
To trigger proteasome activity, mice were treated with
25 mg methylene blue (Panreac AppliChem) per 100 g
of chow, starting from the day of denervation [42].
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Intermittent fasting
Chow was removed from the cages for 24 h, twice a
week, for 4 weeks, starting from the day of denervation.
Trolox
Mice were treated 5 days a week, starting from the day
of denervation, by i.p. injections of 15 mg/kg Trolox
(Sigma) in 40% NaOH in physiologic solution (vehicle)
or an equal volume of vehicle as controls, for 4 weeks.
DNA delivery by electroporation
In anesthetized mice, Tibialis anterior (TA) muscles
were exposed, injected with 25 μl of DNA, containing
8.4 μg of dsRED and 20 micrograms of Ub-G76V-YFP
plasmids, in a 5% mannitol solution, and immediately
subjected to electroporation. 3 days later, mice were
subjected to denervation and then analyzed 2 weeks
following the electroporation.
Histological analyses
TA muscles were dissected, embedded in tissue freezing
medium (Leica, Wetzlar, Germany), and frozen in isopen-
tane pre-cooled with liquid nitrogen. Cryosections (8 μm)
were obtained by using a Leica cryostat. Hematoxylin and
eosin (H&E) and Masson’s trichrome staining (Sigma-
Aldrich) were performed according to the manufacturer’s
instructions.
Dihydroethidium (DHE) staining was performed on
transverse cryosections of TA muscles. Unfixed cryosections
were incubated with 0.002 mM DHE (Molecular Probes
D1168) in DMSO for 30 min at 37 °C. Coverslips were
mounted with 60% glycerol in Tris HCl 0.2 M pH 9.3.
For immune-histochemical analyses, cryosections
were fixed in 4% paraformaldehyde for 10 min at room
temperature, then washed and blocked with 1% BSA
(Sigma, St. Louis, MO) for 30 min or with 5% Goat
serum for 1 h. Samples were then incubated with one
of the following antibodies, diluted in 1% BSA: 1:100
rabbit polyclonal anti-laminin antibody (Sigma), 1:500
mouse monoclonal anti-CD68 (AbD Serotec), 1:100
rabbit polyclonal anti-dystrophin (Abcam), 1:50 rabbit
polyclonal anti-alpha-dystroglycan (Santa Cruz), overnight
at 4 °C. To detect the primary antibody, incubation with a
1:500 dilution of anti-rabbit-Alexa 488 or anti-Rat-Alexa
488 (Life Technologies) secondary antibodies in 1% BSA
for 1 h at room temperature was performed. For IgG
staining, after blocking, muscles were incubated with a
1:500 dilution in 1% BSA of anti-mouse-Alexa 555 (Life
Technologies) secondary antibody, for 1 h at room
temperature. 0.5 μg/ml Hoechst 33,342 (Sigma) was
used to stain nuclei.
Morphometric analyses
Myofiber cross-sectional area, CD68+ area, and connective
tissue were quantified by using ImageJ software. For myo-
fibers distribution analyses, about 600 fibers were counted
for each sample.
RNA extraction and real-time PCR
Total RNA was isolated and purified from 30 to 50 mg
of TA muscles by using Trizol (Invitrogen), following
the manufacturer’s protocol. One microgram of total
RNA was converted to cDNA by using the PrimeScript™
RT reagent Kit (Takara). Real-time PCR was performed
with the SDS-ABI Prism 7500 (Applied Biosystem), by
using the Sybr Green reaction mix (Applied Biosystem).
Primers are listed in Table 1.
Protein extraction and western blot analyses
TA muscles were dissected, minced, and homogenized
in lysis buffer (50 Mm Tris HCl pH 7.4, 1 mM EDTA,
150 Mm NaCl, 1% Triton) supplemented with protease
and phosphatase inhibitors. Proteins (30–50 μg) were
separated by SDS-PAGE and transferred to PVDF mem-
brane (Invitrogen). Unspecific binding was blocked with
5% not fat dry milk in TBST buffer (20 mM Tris-HCl
pH 7.6, 137 mM NaCl, 0.5% Tween 20) then membranes
were incubated overnight at 4 °C, with primary antibody
diluted in 5% BSA (Sigma) in TBST. After washing in
TBST, membranes were incubated with secondary anti-
bodies HRP-conjugate (Bio-Rad 170-6515 or 170-6516)
and signals were detected by luminol-enhancer solution
(Cyanagen). Images were acquired using films or ChemiDoc
MP imaging system (Bio-Rad). Densitometric analyses were
performed by measuring band intensity for each sample
using ImageJ software. The following primary antibodies
were used: Gapdh (Santa Cruz sc-32,233), LC3b (Cell
Signaling 2775), p62 (Sigma P0067), Gp91phox (BD
Transduction Laboratories), MF20 (Developmental Studies
Hybridoma Bank).
Proteasome assay
TA muscles were dissected, minced, and homogenized in
western blot lysis buffer. 10 μg of freshly isolated protein
extracts were used for measuring proteasome activity, by
using the CHEMICON Proteasome Activity Assay Kit
(APT280, Millipore), following manufacturer’s instructions.
Briefly, the extracts were incubated (2 h at 37 °C) with a
labeled substrate, LLVY-7-amino-4-methylcoumarin,
and the cleavage activity was monitored by detection of
the free fluorophore 7-amino-4-methylcoumarin using
a fluorescence plate reader (Infinite F200 PRO, TECAN)
at 360/460 nm.
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Antioxidant enzymes activities
Muscles were homogenized in 100 mM Na-phosphate
buffer pH 7.0 or pH 6.5 depending on the assay, with
protease inhibitors cocktail (Sigma), and centrifuged at
13000 rpm for 15 min at 4 °C. Cytosol proteins were
measured on the resulting supernatant according to the
Bradford method. Glutathione S-transferase activity was
determined by using 1-chloro-2-4-dinitrobenzene (CDNB)
as substrate. The assay was performed at 340–410 nm (ε =
9.6 mM− 1 cm− 1) in a final volume of 1 ml containing
100 mM Na-phosphate buffer pH 6.5, 1 mM CDNB,
1 mM reduced glutathione and 50 μg of protein lysate.
Glutathione reductase activity was measured by the rate of
decrease in absorbance induced by NADPH oxidation, at
340 nm (ε = − 6.22 mM− 1 cm− 1). The assay mixture con-
tained, in a final volume of 1 ml, 100 mM Na-phosphate
buffer pH 7.0, 1 mM glutathione disulfide, 60 μMNADPH,
and 100 mg of protein lysate.
Dichlorodihydrofluorescein assay
Total free radical presence (reactive oxygen species and
reactive nitrogen species) were quantified on muscle
extracts by using OxiSelect Kit from Cell Biolabs, following
the manufacturer’s instructions.
Statistics
Statistical significance was determined by using two-way
analysis of variance (ANOVA) followed by Tukey’s HSD
as a post hoc test. All values are expressed as mean ±
standard error of the mean (SEM). VassarStats, a statistical
computation website available at http://vassarstats.net/,
was used for the statistical analyses.
Results
Skeletal muscles of HDAC4mKO mice lost structural
integrity following long-term denervation
To delineate the role of HDAC4 in skeletal muscle with
a genetic approach following long-term denervation, the
sciatic nerve of HDAC4mKO and control mice was cut,
and TA muscles were analyzed over time. To reduce
the number of experimental animals, contralateral, non-
denervated muscles were used as controls [24]. Muscle
mass evaluation showed that HDAC4mKO mice lost
significantly less TA weight if compared with control
mice, for the first 2 weeks after denervation, as previously
published [31]. Interestingly, at later times, the resistance to
neurogenic muscle atrophy displayed by the HDAC4mKO
mice was lost: indeed, by the fourth week after denervation,
the loss of muscle mass with respect to contralateral
muscles was similar (approximately 40%) for HDAC4mKO
and control mice (Additional file 1: Figure S1a). Immuno-
staining for laminin of TA cross-sections clearly delineated
a decrease of muscle fiber size in control mice upon
denervation, indicative of muscle atrophy (Additional file 1:
Figure S1b). In contrast, the decrease in fiber size was
less evident in the HDAC4mKO denervated muscles,
even 4 weeks following denervation (Additional file 1:
Figure S1b).
We further analyzed muscle histology and observed
that, while denervation induced a reduction of fiber size
in control mice, denervated HDAC4mKO muscles lost
their structural integrity, showing infiltrated mononucle-
ated cells and fibers with heterogeneous sizes (Fig. 1a). Loss
of muscle mass could depend on a decrease in myofiber
number and/or myofiber size. Therefore, we quantified the
myofiber number in each condition and no significant
differences were detected among samples (Fig. 1b).
Morphometric and statistical analyses of the myofiber
cross-sectional area (CSA) distribution confirmed a sig-
nificant effect of denervation in 500–1000, 1500–2000,
and > 2500 square micron classes (Fig. 1b). Moreover,
the analyses revealed a significant higher number of
smaller myofibers (1000–1500 μm²) in contralateral
HDAC4mKO muscles respect to contralateral controls, at
the expenses of the large ones (> 2500 μm²). Conversely,
denervated HDAC4mKO muscles exhibited a signifi-
cantly lower number of small myofibers (1000–
1500 μm²) with respect to denervated control muscles
(Fig. 1b).
To further characterize the HDAC4mKO phenotype
after 4 weeks of denervation, IgG staining was performed
and IgG+ fibers were quantified, detecting a significant
Table 1 Primer used for real-time PCR
Gene Forward Reverse
Atg7 GCCTAACACAGATGCTGCAA TGCTCTTAAACCGAGGCTGT
Gabarapl1 GTGCCGGTCATCGTGGA TCCTCGTGGTTGTCCTCA
p62 CCCAGTGTCTTGGCATTCTT AGGGAAAGCAGAGGAAGCTC
Gsr1 AAT TGG CGT GTT ATT AAG GAA AAG C TCT ATA TGG GAC TTG GTG AGA TTG T
Gstp1 ATG ACT ATG TGA AGG CAC TG AGG TTC ACG TAC TCA GGG GA
NQO1 CAT TCT GAA AGG CTG GTT TGA CTA GCT TTG ATC TGG TTG TCA G
Catalase CCT CCT CGT TCA AGA TGT GGT TTT C CCT CCT CGT TCA AGA TGT GGT TTT C
Gapdh ACCCAGAAGACTGTGGATGG CACATTGGGGGTAGGAACAC
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increase in the presence of necrotic fibers in HDAC4mKO
muscles following denervation, a finding virtually absent
in contralateral muscles and poorly present in denervated
control muscles (Fig. 1c). Since compromised fiber
permeability is often associated with disruption of the
dystrophin-glycoprotein complex (DGC), the expression
and localization of two components of the DGC were
evaluated in HDAC4mKO and control mice, following
4 weeks of denervation. No obvious differences in
dystrophin or alpha-dystroglycan expression pattern were
observed by immunofluorescence analyses (Additional file 1:
Figure S2). The infiltrating mononuclear cells observed
in denervated HDAC4mKO muscles were prevalently
macrophages, as demonstrated by immunofluorescence
Fig. 1 Skeletal muscles lacking HDAC4 shows compromised integrity following long-term denervation. a Hematoxylin and eosin staining of control
(CTR) and HDAC4mKO TA muscles following 4 weeks of denervation. Scale bar = 50 μm. b Number of myofibers in CTR and HDAC4mKO contralateral
and denervated muscles, 4 weeks after denervation. n = 3. Distribution analysis of fiber cross-sectional area of control (CTR) and HDAC4mKO mice,
following 4 weeks of denervation. Data are shown as mean ± SEM; n = 3. Two-way ANOVA revealed an effect of genotype (F = 110.27; df 1; p = 0.001
for > 2500 μm2 class), an effect of denervation (F = 16.93; df 1; p = 0.009 for 500–1000 μm2 class; F = 390.97; df 1; p = 0.001 for 1500–2000 μm2 class
and F = 18.5; df 1; p = 0.007 for > 2500 μm2 class) and an interaction (F = 104.35; df 1; p = 0.001 for 1000–1500 μm2 class and F = 139.33; df 1; p = 0.001
for > 2500 μm2 class); *p < 0.05 by Tukey’s HSD test. c Representative images for laminin (green) and IgG staining (red) of control (CTR) and HDAC4mKO
TA muscles and relative quantification, following 1 week of denervation. Scale bar = 50 μm. n= 3; two-way ANOVA showed an interaction (F = 8.41; df 1;
p = 0.017); *p < 0.05 by Tukey’s HSD test. d Immunostaining for CD68 (green) and laminin (red) of control and HDAC4mKO TA muscles and relative
quantification, following 1 week of denervation. Scale bar = 25 μm. n = 3; two-way ANOVA showed an interaction (F = 9.77; df 1; p = 0.012);
*p < 0.05 by Tukey’s HSD test. e Masson’s trichrome staining of control (CTR) and HDAC4mKO TA muscles and quantification of connective tissue, following
4 weeks of denervation. Scale bar = 25 μm. n= 3; two-way ANOVA showed an interaction (F = 39.42; df 1; p = 0.0004); *p < 0.05 by Tukey’s HSD test.
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and quantitative analyses for CD68 (Fig. 1d). Moreover,
connective tissue was labeled by trichrome staining and
quantified among samples. A significant accumulation
of fibrotic tissue was registered only in denervated
HDAC4mKO following 4 weeks of denervation (Fig. 1e).
HDAC4 mediates the activation of UPS and autophagy in
skeletal muscle upon denervation
Skeletal muscle triggers UPS and autophagy to catabolize
cellular components in response to denervation [4, 43, 44].
Since HDAC4 is a crucial mediator of skeletal muscle
response to denervation, we monitored the activation of
both UPS and autophagy in HDAC4mKO mice, over time.
No significant differences were detected in the proteasome
activity among samples, 1 week following denervation
(Fig. 2a). Myosin heavy chain (MHC) levels were also
monitored by western blot analyses (Fig. 2b), as an
index of proteasome activity. Two-way ANOVA on MHC
densitometry revealed that denervation significantly
modulated MHC levels; however, no differences between
genotypes occurred at this time point (Fig. 2c).
Conversely, 2 weeks following denervation, proteasome
activity was significantly increased in denervated muscles
of control mice, while it resulted not activated in
HDAC4mKO muscles (Fig. 2d). Consistently, MHC
levels significantly decreased in denervated control muscles,
differently from HDAC4mKO mice, 2weeks following
denervation (Fig. 2e, f). We further assessed proteasome
activity by expressing a proteasome activity reporter
plasmid, Ub-G76V-YFP, whose product is normally
degraded by the proteasome and rapidly accumulates if
proteasome activity is impaired [45]. dsRED plasmid
was co-electroporated, in HDAC4mKO and control
skeletal muscles, to monitor transfection efficiency.
3 days later, mice were subjected to denervation and
after 2 weeks YFP+ and RED+ fibers were quantified.
YFP fluorescence was sporadically observed in transfected
control and HDAC4mKO contralateral fibers, but sig-
nificantly increased in HDAC4mKO muscles following
denervation (Fig. 2g), indicating an impairment of UPS
activity.
Proteasome activity did not significantly differ among
samples, 4 weeks after denervation (Fig. 2h), while differ-
ences in MHC levels were detected by western blot analyses
(Fig. 2i). Indeed, denervated control muscles showed a sig-
nificant decrease in MHC levels if compared to contralat-
eral control muscles or denervated HDAC4mKO muscles
(Fig. 2i, l). Overall, these data proved that HDAC4mKO
were unable to activate the proteasome-ubiquitin pathway
following denervation.
To evaluate if HDAC4 mediates autophagy activation,
we evaluated autophagy over time, following denervation.
We first measured the expression of different autophagic
markers in HDAC4mKO and control mice, 1 week after
denervation. As expected, skeletal muscles of control
mice strongly upregulated the expression of autophagic
markers, i.e., Atg7, Gabarapl1, and p62, with respect to
contralateral muscles (Fig. 3a). Interestingly, HDAC4mKO
mice did not increase the expression of any of these
markers following denervation (Fig. 3a). To confirm these
findings, we analyzed LC3b and p62 protein levels (Fig. 3b).
While denervation induced significant accumulation of the
membrane-bound LC3bII and p62 in control mice, the
induction was blunted in denervated HDAC4mKO
muscles (Fig. 3b, c). A reduction in autophagic markers
could depend on either an inhibition of the autophagic
induction or an increase in the autophagic degradation
of the cargo [10]. With the aim to discriminate between
these two possibilities, we monitored the autophagic
flux after administering colchicine (CL), which blocks
the autophagosome-lysosome fusion [46]. CL treatment
induced the accumulation of LC3bII in both contralateral
and denervated muscles in control mice with respect to
untreated ones, as expected (Fig. 3b, c), indicative of a
block in the late stages of the autophagic flux. Similarly,
CL treatment induced an accumulation of LC3bII in
both contralateral and denervated HDAC4mKO muscles
(Fig. 3b, c), indicative of a CL-mediated accumulation of
autophagosomes in HDAC4mKO mice. However, differ-
ently from control mice, p62 protein was not accumulated
after CL treatment in HDAC4mKO mice (Fig. 3b, c).
Taken together, the autophagic flux experiment indicated
that HDAC4mKO mice could form autophagosomes in
response to denervation but displayed a problem in the
autophagic flux between the autophagosome formation
and the autophagosome-lysosome fusion.
Autophagy was further analyzed 2 and 4 weeks following
denervation, by western blot analyses for LC3b and p62.
After 2 weeks of denervation we found that, similarly
to 1 week, denervation significantly increased LC3bII
and p62 protein levels only in control mice (Fig. 3d, e).
After 4 weeks, instead, denervation significantly increased
LC3bII and p62 levels but no differences were registered
between genotypes (Fig. 3f, g).
Methylene blue and intermittent fasting ameliorate
HDAC4mKO muscle following denervation
To evaluate the relative contribution of UPS and of the
autophagic activation to the loss of muscle integrity and
inflammation in HDAC4mKO mice following denervation,
we administered either methylene blue (MB) to activate
the proteasome [42], or intermittent fasting (IF) to
triggered autophagy [47]. We first confirmed that MB
activated UPS in HDAC4mKO mice by measuring
proteasome activity (Additional file 1: Figure S3a). To
further demonstrate that MB effectively activated the
proteasome in HDAC4mKO mice, we evaluated MHC
levels by western blot analyses. MB treatment resulted
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Fig. 2 HDAC4 mediates the activation of ubiquitin-proteasome pathway in skeletal muscle upon denervation. a Proteasome activity in control
(CTR) and HDAC4mKO muscles, 1 week following denervation. n = 3–4. b Representative western blot for MHC protein in control (CTR) and
HDAC4mKO muscles, 1 week following denervation. Gapdh was used as loading control. c Densitometric measurements of MHC protein, 1 week
following denervation. n = 4. d Proteasome activity in control (CTR) and HDAC4mKO muscles, 2 weeks following denervation. Data are shown as
mean ± SEM; n= 3–4. Two-way ANOVA revealed an interaction (F= 5.48; df 1; p= 0.03); *p< 0.05 by Tukey’s HSD test. e Representative western blot for
MHC protein in control (CTR) and HDAC4mKO muscles, 2 weeks following denervation. Gapdh was used as loading control. f Densitometric measurements
of MHC protein, 2 weeks following denervation. n= 4; two-way ANOVA revealed an interaction (F = 4.96; df 1; p = 0.046); *p < 0.05 by Tukey’s HSD test.
g Representative pictures of control (CTR) and HDAC4mKO muscles electroporated with Ub-G76 V-YFP (green), a UPS activity reporter and
dsRED (red) plasmids, for monitoring the efficiency of electroporation, 2 weeks after denervation. Scale bar = 50 μm. Quantification of green
and red positive fibers. n = 3; between 50 and 300 dsRED+ fibers were counted per sample. Two-way ANOVA revealed an interaction (F = 5.48; df 1;
p = 0.03); *p < 0.05 by Tukey’s HSD test. h Proteasome activity in control (CTR) and HDAC4mKO muscles, 4 weeks following denervation. Data are
shown as mean ± SEM; n = 3–4. i Representative western blot for MHC protein in control (CTR) and HDAC4mKO muscles, 4 weeks following
denervation. Gapdh was used as loading control. l Densitometric measurements of MHC protein, 4 weeks following denervation. n = 4; two-way
ANOVA revealed an interaction (F = 5.25; df 1; p = 0.04); *p < 0.05 by Tukey’s HSD test.
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Fig. 3 HDAC4 mediates the activation of autophagy in skeletal muscle upon denervation. a Real-time PCR for autophagic markers in control (CTR) and
HDAC4mKO skeletal muscle, 1 week following denervation. Data are shown as mean ± SEM; n = 8; two-way ANOVA revealed an interaction (F = 29.3;
df 1; p = 0.001 for Atg7; F = 28.5; df 1; p = 0.001 for Gabarapl1; F = 9.65; df 1; p = 0.004 for p62); **p < 0.01 by Tukey’s HSD test. b Representative western
blot for LC3b and p62 proteins in control (CTR) and HDAC4mKO TA muscles, 1 week following denervation, in the absence (−) or after colchicine (CL)
treatment. Gapdh was used as loading control. c Densitometric analyses for LC3b and p62 proteins, 1 week following denervation, in the absence (−)
or after colchicine (CL) treatment. Data are shown as mean ± SEM; n = 3–4; two-way ANOVA revealed an interaction (F = 114; df 1; p = 0.001 for LC3b;
F = 14.29; df 1; p = 0.036 for p62); *p < 0.05 versus CTR Con; $p < 0.05 versus CTR Den by Tukey’s HSD test. d Representative western blot for LC3b and
p62 proteins, 2 weeks following denervation. Gapdh was used as loading control. e Densitometric measurements for LC3b and p62 proteins, 2 weeks
following denervation. n = 3–4; two-way ANOVA revealed an interaction (F = 13.21; df 1; p = 0.046 for LC3b; F = 7.35; df 1; p = 0.01 for p62); *p < 0.05
versus CTR Con by Tukey’s HSD test. f Representative western blot analyses for LC3b and p62, 4 weeks after denervation. Gapdh was used as loading
control. g Densitometric measurements for LC3b and p62 proteins, 4 weeks following denervation. n = 4; two-way ANOVA revealed an effect of
denervation (F = 6.34; df 1; p = 0.028 for LC3b; F = 10.68; df 1; p = 0.0061 for p62)
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in lower MHC levels in HDAC4mKO mice, whereas
denervation did not affect MHC levels in untreated
HDAC4mKO mice (Additional file 1: Figure S3b).
Moreover, the proteasome reporter activity plasmid,
Ub-G76 V-YFP, was transfected with dsRED in
HDAC4mKO mice, and YFP+ and RED+ fibers were
counted 2 weeks following denervation, without or
with MB treatment (Additional file 1: Figure S3c).
Quantification of YFP+ and RED+ fibers proved that MB
treatment efficiently reduced the YFP+ fibers accumulated
in HDAC4mKO upon denervation (Additional file 1:
Figure S3c). We also proved that IF significantly upreg-
ulated gene expression and protein levels of autophagic
markers in HDAC4mKO mice (Additional file 1: Figure
S3d and e).
In order to assess the bearing of forced activation of
the catabolic pathways upon the loss of muscle integrity
and inflammation, HDAC4mKO mice were subjected to
either MB treatment or IF since the day of surgery, and
histological and morphometric analyses were performed
4 weeks following denervation. Strikingly, HDAC4mKO
muscles treated with either MB or IF displayed a better
preserved structural integrity, following denervation (Fig. 4a).
No significant differences in the number of myofibers were
registered among samples; while, analysis of myofiber
CSA distribution revealed that both MB- and IF-treated
HDAC4mKO mice displayed a significant higher number
of larger myofibers (2500–3000 μm²) in contralateral mus-
cles and an increase in the number of smaller myofibers
(1000–1500 μm²) following denervation, with respect to
untreated HDAC4mKOmice (Fig. 4b and Additional file 1:
Figure S4a and b). However, no effects were registered
on muscle mass following treatments (Additional file 1:
Figure S4c). Furthermore, muscle integrity, macrophagic
infiltration and amount of connective tissue were evaluated.
Quantification of IgG+ fibers, CD68+, or Masson’s tri-
chrome+ area showed that both MB and IF treatments
reduced necrotic fibers, macrophagic infiltration, and
connective tissue in denervated HDAC4mKO muscles
(Fig. 4c–e).
HDAC4 mediates the activation of OS response in skeletal
muscle upon denervation
Since HDAC4 modulates skeletal muscle response
following denervation, which increases the levels of OS,
we wondered whether HDAC4 mediates the response
to OS. Oxidative stress response and oxidative stress levels
were evaluated over time. Reactive oxygen species (ROS)
levels were assessed and quantified by dihydroethidium
(DHE) staining, at 1, 2, and 4 weeks following denervation.
Unlike control mice, which showed significant upregula-
tion of DHE intensity, HDAC4mKO mice did not display
increased levels of ROS 1 week following denervation
(Fig. 5a). This result was corroborated by the evaluation of
Gp91phox, a marker of OS. Indeed, densitometric analysis
of Gp91phox levels showed a significant increase in
denervated control muscles, if compared to contralateral
ones. Conversely, in HDAC4mKO mice, the increase of
Gp91phox levels 1 week following denervation was signifi-
cantly blunted (Fig. 5b and Additional file 1: Figure S5a).
Oxidative stress was also quantified from muscle extracts
by measuring free radical levels. Denervation significantly
increased ROS and reactive nitrogen species (RNS) in
control muscles, but not in HDAC4mKO mice, 1 week
following denervation (Fig. 5c). Moreover, we quantified
gene expression of several genes involved in the oxidative
stress response, i.e., glutathione reductase (GSR), glutathione
S-transferase (GST), NAD(P)H dehydrogenase [quinone] 1
(NQO1), and catalase (Fig. 5d). For these markers, the
expression resulted significantly upregulated following
denervation in controls but not in HDAC4mKO muscles
(Fig. 5d). The enzymatic activity of glutathione reductase
and glutathione S-transferase showed the same modula-
tion as the expression levels (Fig. 5e), confirming that
control mice significantly upregulated the OS response
following denervation, while HDAC4mKO mice did not
increase either the expression or the enzymatic activity of
genes involved in the OS response.
Oxidative stress was further analyzed after 2 and
4 weeks of denervation. After 2 weeks, we observed that
denervation increased OS levels only in control mice
(Fig. 5f, g and Additional file 1: Figure S5b), similarly to
1 week following denervation. After 4 weeks, although
denervation resulted in a significant increase of OS in
both control and HDAC4mKO mice (Fig. 5h, i and
Additional file 1: Figure S5c), gene expression of GSR,
GST, NQO1, and catalase resulted not significantly modu-
lated in denervated HDAC4mKOmuscles (Additional file 1:
Figure S5d). These data point to the importance of
HDAC4 in activating the OS response following denervation
in skeletal muscle.
Administration of an antioxidant drug prevents the loss
of structural integrity in HDAC4mKO muscles following
denervation
Since HDAC4mKO mice did not activate OS response
upon denervation, to evaluate if the impairment contrib-
uted to HDAC4mKO skeletal muscle integrity following
denervation, we treated HDAC4mKO mice with Trolox,
a cell-permeable derivative of vitamin E with antioxidant
properties [24, 48, 49], for 4 weeks, after the surgery.
Administration of Trolox efficiently reduced ROS levels in
HDAC4mKOmice following denervation (Additional file 1:
Figure S6a and b). Strikingly, Trolox treatment significantly
increased muscle mass of HDAC4mKO mice following
denervation (Fig. 6a). Histological analyses showed that
HDAC4mKO muscle architecture was more preserved
upon denervation following Trolox treatment (Fig. 6b).
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Fig. 4 Methylene blue and intermittent fasting preserve HDAC4mKO skeletal muscle structure following denervation. a Hematoxylin and eosin staining of
HDAC4mKO contralateral and denervated muscles, 4 weeks after denervation, without (−) or after MB or IF treatment. Scale bar = 50 μm. b Number of
myofibers in HDAC4mKO contralateral and denervated muscles, 4 weeks after denervation, without (−) or after MB or IF treatment. n = 3. Number of
HDAC4mKO myofibers with 2500–3000 or 1000–1500 μm2 cross-sectional area, without (−) or after MB or IF treatment, 4 weeks after denervation. Data are
shown as mean ± SEM; n= 4; two-way ANOVA revealed an interaction (F = 6.72; df 1; p = 0.02 for MB; F = 8.2; df 1; p = 0.01 for IF) (F = 7.27; df 1; p = 0.026 for
MB; F = 10.2; df 1; p = 0.01 for IF); **p< 0.01 by Tukey’s HSD test. c HDAC4mKO muscle sections labeled with laminin (green) and IgG (red), 4 weeks after
denervation, without (−) or after MB or IF treatments, with relative quantification. Scale bar = 50 μm. n= 3; two-way ANOVA showed an interaction (F = 10.82;
df 1; p = 0.0094 for MB; F = 11.43; df 1; p =0.0081 for IF); *p < 0.05 by Tukey’s HSD test. d Immunostaining for CD68 (green) and laminin (red) of HDAC4mKO
muscles 4 weeks after denervation, without (−) or after MB or IF treatment, with relative quantification. Scale bar = 25 μm. n = 3; two-way ANOVA showed an
interaction (F = 6.57; df 1; p = 0.03 for MB; F = 6.06; df 1; p = 0.036 for IF); *p < 0.05 by Tukey’s HSD test. e Masson’s trichrome staining of HDAC4mKO
contralateral and denervated muscles, 4 weeks after denervation, without (−) or after MB or IF treatment, with relative quantification. Scale bar = 50 μm. n = 3;
two-way ANOVA showed an interaction (F = 53.95; df 1; p = 0.001 for MB and F = 59.36; df 1; p = 0.0001 for IF); *p < 0.05 by Tukey’s HSD test.
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Fig. 5 HDAC4 mediates the activation of OS response in skeletal muscle upon denervation. a DHE staining of control (CTR) and HDAC4mKO TA
muscles following 1 week of denervation and relative quantification. Scale bar = 50 μm. n = 5; two-way ANOVA showed an interaction (F = 8.74;
df 1; p = 0.01); *p < 0.05 by Tukey’s HSD test. b Densitometric analysis of western blots for Gp91phox in CTR and HDAC4mKO TA muscles, 1 week
after denervation. n = 4; two-way ANOVA showed an interaction (F = 20.14; df 1; p = 0.0004); *p < 0.05 by Tukey’s HSD test. c Quantification of
ROS and RNS 1 week of denervation. n = 4–5; two-way ANOVA revealed an effect of denervation (F = 9; df 1; p = 0.009) and an interaction (F = 5;
df 1; p = 0.041); *p < 0.05 by Tukey’s HSD test. d Real-time PCR of antioxidant enzymes in CTR and HDAC4mKO skeletal muscles, 1 week following
denervation. n = 4–5; two-way ANOVA revealed an interaction (F = 8.82; df 1; p = 0.0082 for GSR; F = 5.24; df 1; p = 0.03 for GST; F = 14.07; df 1;
p = 0.0015 for NQO1 and F = 6.14; df 1; p = 0.02 for catalase); *p < 0.05; **p < 0.01 by Tukey’s HSD test. e Activity of GSR and GST, 1 week following
denervation. n = 5–6; two-way ANOVA showed an interaction (F = 11.16; df 1; p = 0.0026 for GSR; F = 6.16; df 1; p = 0.026 for GST); *p < 0.05 by Tukey’s
HSD test. f DHE staining of CTR and HDAC4mKO TA muscles following 2 weeks of denervation. Scale bar = 50 μm. g Densitometric analysis of western
blots for Gp91phox in CTR and HDAC4mKO TA muscles, 2 weeks after denervation. n = 4; two-way ANOVA showed an interaction (F = 36.77;
df 1; p = 0.0001); *p < 0.05 by Tukey’s HSD test. h DHE staining of CTR and HDAC4mKO TA muscles following 4 weeks of denervation. Scale
bar = 50 μm. i Densitometric analysis of western blots for Gp91phox in CTR and HDAC4mKO TA muscles, 4 weeks after denervation. n = 4;
two-way ANOVA revealed an effect of denervation (F = 14.97; df 1; p = 0.0026)
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Fig. 6 (See legend on next page.)
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Morphometric analyses demonstrated that Trolox
neither significantly affected the number of myofibers in
HDAC4mKO mice nor myofiber distribution (Fig. 5c),
retaining the resistance to neurogenic muscle atrophy.
IgG and immunostaining analyses revealed that Trolox
significantly reduced the number of necrotic fibers
(Fig. 6d), macrophagic infiltration (Fig. 6e), and connective
tissue (Fig. 6f) in denervated HDAC4mKO muscles with
respect to untreated once.
Discussion
HDAC4 is a crucial mediator of skeletal muscle response
to denervation, contributing to the induction of the
expression of the muscle-specific E3 ubiquitin-ligases and
miR-206, and activating the MAPK-AP1 axis [31, 35].
Numerous pathologies that affect the peripheral nervous
system, causing the loss or the alteration of nervous
stimuli, lead to decreased skeletal muscle mass and
functionality. Even in sarcopenia, the age-related loss of
skeletal muscle mass, a strong association between
motoneuron impairment and the degree of muscle
wasting has been established. Indeed, numerous studies
showed that degeneration and loss of motor neurons
followed by structural and functional changes in inner-
vations, significantly contribute to the progression of
sarcopenia [50–52]. Considering the central role in
mediating skeletal muscle nerve response, several studies
indicated HDAC4 as a potential therapeutic target for the
prevention of neurogenic muscle atrophy in pathological
conditions or during aging [38, 53]. In all these conditions,
the proposed treatments should be prolonged for months
or years. In the present work, we proved that inhibition of
HDAC4 in long-term denervation condition is deleterious
for skeletal muscle. Contrary to controls, HDAC4mKO
mice showed loss of skeletal muscle integrity, characterized
by the presence of necrotic fibers, macrophage infiltration,
accumulation of connective tissue, and heterogeneity in
myofiber size following 4 weeks of denervation. However,
no significant differences in myofiber number or muscle
weights were registered between HDAC4mKO and control
mice, thus suggesting that loss of muscle mass in
HDAC4mKO mice depends on loss of muscle integrity and
not merely on muscle atrophy.
To investigate the molecular mechanisms underlying
this phenotype, we evaluated the activation of the cata-
bolic pathways triggered in neurogenic muscle atrophy,
i.e., the UPS and autophagy. Indeed, if UPS or autophagic
hyper-activation leads to muscle atrophy [54, 55], their
impairment in conditions in which they must be activated
is deleterious for skeletal muscle [56, 57]. While control
mice activated the proteasome and degraded MHC upon
denervation, HDAC4mKO mice did not show either
proteasome activation or decrease in MHC levels, until
4 weeks following denervation, indicating an impairment
in the ubiquitin-proteasome system response. Autophagic
flux experiments demonstrated that autophagosome
formation occurred in HDAC4mKO muscles, 1 week
following denervation. However, accumulation of autophagic
intermediates failed in HDAC4mKO upon denervation, after
1 and 2 weeks. After 4 weeks, instead, denervation
significantly increased LC3bII and p62 both in control
and HDAC4mKO mice, indicating that autophagy was
induced also in muscles with HDAC4 deletion.
Although proteasome inhibitors can hinder muscle
atrophy in different animal models [58–60], long-term
inhibition of this pathway could be deleterious for
muscle cells. Indeed, the administration of Bortezomib,
a proteasome inhibitor, FDA-approved for the treatment
of multiple myeloma, causes cardiac complications in
chronic patients [61]. This observation is in accordance
with our results, which showed that long-term inhibition
of the UPS, upon denervation, induced loss of muscle
integrity, similarly to mice null for MuRF1 [55].
As for UPS, autophagy plays a major role in removing
damaged mitochondria and in mediating the metabolic
response of skeletal muscle to denervation, without inducing
neurogenic muscle atrophy [24]. A proper autophagic
response or flux is crucial for the maintenance of skeletal
muscle homeostasis, both in physiological and in patho-
logical conditions [41, 62, 63]. By triggering either UPS or
(See figure on previous page.)
Fig. 6 Administration of an antioxidant drug ameliorates HDAC4mKO muscle structure following denervation. a Weight of HDAC4mKO TA
muscles without (−) or with Trolox (TRX) treatment, over contralateral ones, 4 weeks after denervation. Data are shown as mean ± SEM; n = 3;
two-way ANOVA revealed an interaction (F = 12; df 1; p = 0.0085); *p < 0.05 by Tukey’s HSD test. b Hematoxylin and eosin staining of HDAC4mKO
contralateral and denervated muscles, 4 weeks after denervation, without (−) or with Trolox treatment. Scale bar = 50 μm. c Number of myofibers in
HDAC4mKO contralateral and denervated muscles, 4 weeks after denervation, without (−) or after Trolox treatment. n = 3. Quantitative distribution
analysis of fiber cross-sectional area of HDAC4mKO mice, following 4 weeks of denervation, without or with Trolox treatment. Data are shown
as mean ± SEM. n = 3; two-way ANOVA revealed an effect of denervation (F = 7.25; df 1; p = 0.021 for 500–1000 μm2 class). d HDAC4mKO muscles
labeled for laminin (green) and IgG (red), 4 weeks after denervation and relative quantification. Scale bar = 50 μm. n = 3; two-way ANOVA revealed an
interaction (F = 9.26; df 1; p = 0.013); *p < 0.05 by Tukey’s HSD test. e Immunostaining for CD68 (green) and laminin (red) of HDAC4mKO muscles,
4 weeks after denervation, without (−) or with Trolox treatment, with relative quantification. Scale bar = 25 μm. n = 3; two-way ANOVA revealed an
interaction (F = 6.07; df 1; p = 0.035); *p < 0.05 by Tukey’s HSD test. f Masson’s trichrome staining of HDAC4mKO contralateral and denervated muscles,
4 weeks after denervation, without (−) or with Trolox treatment, with relative quantification. Scale bar = 50 μm. n = 3; two-way ANOVA revealed an
interaction (F = 38.75; df 1; p = 0.0003); *p < 0.05 by Tukey’s HSD test.
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autophagy, loss of membrane integrity, inflammatory infil-
tration, and accumulation of fibrotic tissue were efficiently
rescued in HDAC4mKO mice upon long-term denervation.
Moreover, morphometric measurements of myofiber
cross-sectional area confirmed that the treatments induced
a change in denervated and contralateral HDAC4mKO
muscle fiber size, restoring a myofiber distribution similar
to that of control mice.
OS plays a dualistic role in skeletal muscle: on the one
hand, low levels of OS contribute to the maintenance of
muscle homeostasis in different physiological conditions,
e.g., physical activity [64–66]; on the other hand, excessive
ROS production leads to alteration of skeletal muscle
homeostasis and is involved in muscle damage in several
pathological conditions [67–69]. Since neurodegenerative
conditions and aging have been associated with chronically
elevated levels of ROS, antioxidant treatments have been
proposed or are currently in clinical trial [70–72]. In our
work, we observed that HDAC4mKO mice neither
increased the levels of ROS and RNS in skeletal muscle
nor induced the expression and activation of the enzymes
involved in the antioxidant response, 1 week following
denervation. 2 weeks following denervation, HDAC4mKO
mice still showed decreased levels of OS, compared to
control mice. After 4 weeks, although no significant differ-
ences in OS levels were registered between the genotypes,
HDAC4mKO mice still showed compromised activation
of the expression of genes involved in the OS response.
Therefore, we speculate that the changes in OS levels
observed following 4 weeks of denervation are a conse-
quence of loss of muscle integrity. Importantly, antioxidant
treatment, not only prevented loss of muscle integrity in
HDAC4mKO mice, with a reduction of necrotic fibers,
macrophagic infiltration, and connective tissue but also
preserved muscle mass in denervated muscles. In other
words, antioxidant treatment preserved all the positive
effects of HDAC4 deletion in skeletal muscle following
denervation, i.e., the resistance to neurogenic muscle
atrophy, abrogating the negative consequences of a pro-
longed inhibition of the catabolic pathways, i.e., loss of
structural integrity. Our data are in apparent contrast
with the study in which administration of a pan-HDAC
inhibitor prevents muscle atrophy following denervation,
by increasing OS response and reducing oxidative damage
[54]. However, the experimental differences between the
two studies must be considered: (1) pan-HDAC inhibitors
not specifically inhibit all members of HDAC superfamily;
(2) systemic administration of HDAC inhibitors affects all
tissues, differently from studying the effects on a tissue-
specific KO mouse; (3) administration of HDAC inhibitors
starting 3 weeks before denervation may provide different
results from the deletion of HDAC4 since the embryonic
stage E8.5, as in HDAC4mKO mice. Of note, independent
groups showed a toxic effect of the Cre recombinase
expression in different murine tissues [73–77]. Although a
toxic effect of the myogenin;Cre mouse line was not
reported, we cannot rule out the possibility that some
of the effects in HDAC4mKO mice depended on Cre
expression.
Conclusion
In conclusion, our results reveal a novel role of HDAC4
in mediating the activation of OS response, UPS, and
autophagy in skeletal muscle following denervation. We
clearly showed that inhibition of HDAC4 could be deleteri-
ous for skeletal muscle in long-term denervation conditions,
such as aging or neuromuscular disorders. These findings
are relevant considering potential therapies for neurogenic
muscle atrophy based on HDAC inhibitors. Indeed, HDAC
inhibitors have been strongly recommended for the treat-
ment of neurodegenerative diseases. However, neither the
molecular mechanisms underlying their actions nor the
possible long-term collateral effects have been clarified
yet. Treatment with HDAC inhibitors may indirectly
affect the acetylation of HDAC4 targets since HDAC4
does not possess direct histone deacetylase activity but
acts through class I HDACs. By delineating new functions
of HDAC4 in neurogenic muscle atrophy, our work repre-
sents a step-forward toward the development of efficient
pharmaceutical approaches for neurogenic muscle atrophy,
possibly by combining HDAC inhibitors with antioxidant
drugs or with other treatments aiming to boost the cata-
bolic pathways in skeletal muscle, otherwise compromised
using HDAC inhibitors.
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